ACC/AHA/SCAI guideline summary: Use of glycoprotein (GP) IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention (PCI)
Class I - There is evidence and/or general agreement that patients undergoing PCI should be given GP IIb/IIIa inhibitors in the following setting:
[Bullet]  Abciximab, eptifibatide, or tirofiban without clopidogrel for a non-ST elevation acute coronary syndrome (ACS)*
Class IIa - The weight of evidence or opinion is in favor of the usefulness of GP IIb/IIIa inhibitors in patients undergoing PCI in the following settings:
[Bullet]  Abciximab, eptifibatide, or tirofiban with clopidogrel for a non-ST elevation ACS.*
[Bullet]  Abciximab as early as possible for ST elevation MI.
[Bullet]  Abciximab, eptifibatide, or tirofiban at the time of elective PCI with stent placement.
Class IIb - The weight of evidence or opinion is less well established for the usefulness of GP IIb/IIIa inhibitors in patients undergoing PCI in the following setting:
[Bullet]  Eptifibatide or tirofiban for ST elevation MI.

* It is acceptable to administer the GP IIb/IIIa inhibitor before performance of the diagnostic angiogram ("upstream treatment) or just before PCI ("in-lab" treatment).

Data from Smith, SC Jr, Feldman, TE, Hirshfeld, JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention a report of the American College of Cardiology/American Heart Association